Thomas Lavery IV
at Amgen Inc
Thomas Lavery IV is a senior patent counsel for Amgen Inc. His main responsibilities include managing large patent litigations that tackle highly complex IP and statutory issues, assessing the strengths and weaknesses of patent portfolios and determining probable litigation outcomes and market entry dates for biosimilar products. He also composes opinions concerning patent validity, infringement and freedom-to-operate clearances.
Before joining Amgen, Mr Lavery was an associate at Goodwin Procter LLP, helping to lead patent litigations for both plaintiffs and defendants in first-to-file Paragraph IV Hatch-Waxman cases and multiple-defendant abbreviated new drug application drug challenges. He also composed comprehensive patent portfolio summary documents.
Before attending law school, Mr Lavery worked as a bioinformatics programmer for the Human Genome Project at the Broad Institute. His work, as part of a multidisciplinary team of biologists and bioinformatics programmers, culminated in a landmark paper with Eric Lander that was published in Nature and provided foundational data for the International Haplotype Map Project.
Mr Lavery holds a JD from Cornell Law School and a BS in biochemistry from Tufts University. He has also earned numerous certificates in programming, data analysis and statistics. He is a member of the American Society of Legal Writers and the Los Angeles Intellectual Property Law Association.
- American Society of Legal Writers
- Pharmaceuticals/life sciences
Thousand Oaks CA